Pan, M.; Trieu, M.K.; Sidhu, M.; Yu, J.; Seto, T.; Ganjoo, K.
Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma. Cancers 2021, 13, 1983.
https://doi.org/10.3390/cancers13081983
AMA Style
Pan M, Trieu MK, Sidhu M, Yu J, Seto T, Ganjoo K.
Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma. Cancers. 2021; 13(8):1983.
https://doi.org/10.3390/cancers13081983
Chicago/Turabian Style
Pan, Minggui, Maily K. Trieu, Manpreet Sidhu, Jeanette Yu, Tiffany Seto, and Kristen Ganjoo.
2021. "Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma" Cancers 13, no. 8: 1983.
https://doi.org/10.3390/cancers13081983
APA Style
Pan, M., Trieu, M. K., Sidhu, M., Yu, J., Seto, T., & Ganjoo, K.
(2021). Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma. Cancers, 13(8), 1983.
https://doi.org/10.3390/cancers13081983